NIH Directors Transformative Research Awards (R01 Clinical Trial Optional) (RFA-RM-20-013)

Sponsor: Office of Strategic Coordination (Common Fund)

Award: NIH intends to commit approximately $8 million in FY 2021 and make approximately seven awards, depending on the size and scope of the most meritorious awards.

Due Date: September 30, 2020

NIH Directors Early Independence Awards (DP5 Clinical Trial Optional) (RFA-RM-20-014)

Sponsor: Office of Strategic Coordination (Common Fund)

Award: The NIH Common Fund intends to commit approximately $4 million to support approximately 10 awards in FY 2021. T

Due Date: September 4, 2020

Department of Defense Peer Reviewed Alzheimer’s Research Program Funding Opportunities

Sponsor: Encompasses several FOAs. (To see individual FOAs, click on "FY20 PRARP Funding Opportunities Now Available!" in left rail.)

Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions (NOT-OD-20-106)

Sponsor: National Institutes of Health

NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) (RFA-RM-20-011)

Sponsor: Office of Strategic Coordination (Common Fund)

Award: NIH intends to commit approximately $8 million in FY 2021 to fund approximately seven awards.

Due Date: September 11, 2020

NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) (RFA-RM-20-012)

Sponsor: Office of Strategic Coordination (Common Fund)

Award: NIH intends to commit approximately $80 million for approximately 33 awards in FY 2021. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: August 21, 2020

Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional) (PAR-20-180)

Sponsor: National Institutes of Health

Due Date: Standard dates apply. The first standard due date for this FOA is October 5, 2020.

Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional) (PAR-20-179)

Sponsor: National Institutes of Health

Award: Standard dates apply. The first standard due date for this FOA is October 05, 2020.

Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Exploratory Grant Program in Parkinson's Disease Research (P20- Clinical Trial Optional) (P20 Clinical Trial Optional) (NOT-NS-

Sponsor: National Institute of Neurological Disorders and Stroke

Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional) (NOT-NS-20-057)

Sponsor: National Institute of Neurological Disorders and Stroke

2020 ADDF-Harrington Scholar Award

Sponsor: Alzheimer's Drug Discovery Foundation and the Harrington Discovery

Award: Up to $600,000 over two years

Due Date: May 18, 2020, at 5 p.m. EDT

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) (PA-20-166)

Sponsor: National Institutes of Health

Due Date: Due dates vary by awarding IC.

Independent Scientist Award (Parent K02 - Independent Clinical Trial Required) (PA-20-171)

Sponsor: National Institutes of Health

Due Date: Standard dates apply.

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required) (PA-20-173)

Sponsor: National Institutes of Health

Due Date: Standard dates apply.

Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed) (PA-20-174)

Sponsor: National Institutes of Health

Due Date: Standard dates apply.